Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the retinitis pigmentosa market grown in recent years?

In the past few years, there has been substantial growth in the retinitis pigmentosa market size. The market, valued at $11.32 billion in 2024, is projected to escalate to $12.22 billion in 2025, experiencing an 8.0% compound annual growth rate (CAGR). Factors contributing to the growth in the historic period include advancements in genetic research, the evolution of retinal imaging technologies, heightened awareness initiatives, the surge of patient advocacy groups, and the broadening of clinical trial networks.

How is the retinitis pigmentosa market size expected to evolve during the forecast period?

The retinitis pigmentosa market size is expected to see strong growth in the next few years. It will grow to $16.37 billion in 2029 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to advancements in stem cell research for retinal regeneration, personalized medicine approaches, increased investment in orphan drug development, and expansion of telemedicine services. Major trends in the forecast period include a shift towards combination therapies, a rise in patient-centric clinical trial designs, the adoption of value-based pricing models, and the integration of digital therapeutics.

Get your retinitis pigmentosa market report here!

https://www.thebusinessresearchcompany.com/report/retinitis-pigmentosa-global-market-report

Which key drivers are propelling the retinitis pigmentosa market’s growth?

The surge in healthcare spending is anticipated to drive the expansion of the retinitis pigmentosa market. Healthcare spending pertains to the total funds allocated on healthcare products and services, including medical procedures, medicines, hospital stays, and preventive healthcare, within a designated timeframe, signifying the overall expense of healthcare provision within a specific population. The escalation in healthcare spending is attributable to the rising cost of advanced medical technologies, an aging demographic, and the widespread occurrence of chronic ailments. Funds designated for retinitis pigmentosa healthcare are primarily being utilized for improving diagnostic techniques, pioneering effective treatments, and offering supportive care to manage vision impairment. For instance, in January 2024, the National Institutes of Health, a governmental agency based in the US, stated that healthcare spending in the US escalated by 4.1% in 2022, touching $4.5 trillion, marking a higher growth rate than the 3.2% increase witnessed in 2021. Hence, the surge in healthcare spending is fuelling the growth of the retinitis pigmentosa market.

What are the market segments in the retinitis pigmentosa industry?

The retinitis pigmentosa market covered in this report is segmented –

1) By Type: Autosomal Recessive, Autosomal Dominant, X-Linked

2) By Treatment: Vitamin A, Docosahexaenoic Acid (DHA), Calcium Channel Blockers, Gene Therapy, Retinal Eye Prosthetics, Other Treatments

3) By Diagnosis: Electroretinogram, Visual Field Testing, Genetic Testing, Other Diagnosis

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-users: Hospitals, Specialty Clinics, Homecare, Other End-users

Subsegments:

1) By Autosomal Recessive: Early-Onset Autosomal Recessive Retinitis Pigmentosa, Late-Onset Autosomal Recessive Retinitis Pigmentosa

2) By Autosomal Dominant: Early-Onset Autosomal Dominant Retinitis Pigmentosa, Late-Onset Autosomal Dominant Retinitis Pigmentosa

3) By X-Linked: X-Linked Recessive Retinitis Pigmentosa, X-Linked Dominant Retinitis Pigmentosa

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16528&type=smp

Which leading companies are shaping the growth of the retinitis pigmentosa market?

Major companies operating in the retinitis pigmentosa market are Johnson & Johnson, Novartis AG, AbbVie Inc., Astellas Pharma Inc., Biogen Inc., Sun Pharmaceutical Industries Ltd, Spark Therapeutics, REGENXBIO Inc., Editas Medicine, IVERIC bio, MeiraGTx Holdings, Gensight Biologics, Second Sight Medical Products, Copernicus Therapeutics Inc., Kiora Pharmaceuticals, 4D Molecular Therapeutics, ReNeuron Group, Acucela Inc., AGTC (Applied Genetic Technologies Corporation), Editgene

What key trends are currently impacting the retinitis pigmentosa market’s development?

Leading firms in the retinitis pigmentosa market are now concentrating on pioneering new treatment modalities like gene therapy, to offer more precise and powerful solutions to manage and possibly cure this incapacitating disease. Gene therapy approach for retinitis pigmentosa (RP) consists of the introduction of functional genes to repair or replace defective ones that lead to this disease. The primary goal of this cutting-edge treatment is to revive the normal operations of damaged photoreceptor cells in the retina, thus potentially curtailing or even stopping the progression of vision loss. For example, ViGeneron GmbH, a biotech company based in Germany, sequentially initiated a Phase Ib clinical trial in April 2024 to scrutinize the safety, tolerability, and effectiveness of VG901, a gene therapy specifically developed for RP induced by CNGA1 gene mutations. It’s an open-label, single-arm, dose-escalation study focused on examining the intravitreal injection of VG901 in patients suffering from autosomal recessive RP owing to biallelic CNGA1 mutations.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16528

Which regions are most influential in expanding the retinitis pigmentosa market?

North America was the largest region in the retinitis pigmentosa market in 20244 The regions covered in the retinitis pigmentosa market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Transthyretin Amyloidosis Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/transthyretin-amyloidosis-treatment-global-market-report

Vitreoretinal Surgery Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/vitreoretinal-surgery-devices-global-market-report

Retinal Vein Occlusion Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/retinal-vein-occlusion-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: